← Back to all signals
RESEARCH PAPER ANALYSIS

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

AI interpretation is pending for this paper.

Open original publication →
PMID41591981
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Publication Date2026-04-01
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

PURPOSE: Arm D of the AcSé-ESMART proof-of-concept phase I/II platform trial aimed to define the recommended phase II dose (RP2D), pharmacokinetics, activity, and biomarkers of the PARP inhibitor olaparib with irinotecan in pediatric patients with recurrent/refractory malignancies. PATIENTS AND METHODS: Olaparib was administered orally twice daily on days 1 to 10 and irinotecan intravenously on days 4 to 8 of a 21-day cycle. Dose escalation followed the continuous reassessment method; activity was assessed in diverse tumor types (cohort 1) and Ewing sarcoma (cohort 2) according to a minimax Simon 2-stage design. Cohorts were enriched for alterations in homologous recombination repair (HRR) pathways. RESULTS: Seventy patients (median age, 14.9 years; range, 5.0-23.8) were included, 34 with diverse tumor types (25 with HRR gene alterations) and 36 with Ewing sarcoma. Sixty-six patients received 348 treatment cycles (median, 2; range, 1-51) over four dose levels. Main toxicities were gastrointestinal and myelosuppression; the RP2D was olaparib 90 mg/m2 twice daily and irinotecan 20 mg/m2/day. Olaparib exposure in children was equivalent to that in adults. The overall response rate was 9.1% (cohort 1, 11.8%; cohort 2, 6.3%). Four patients with osteosarcoma, pineoblastoma, choroid plexus carcinoma, and neuroblastoma experienced a partial response and were treated for nine to 51 cycles. Two patients with Ewing sarcoma experienced a complete and a partial response for 10 and 42 cycles, respectively. Genetic analyses suggest a high aneuploidy score possibly associated with objective response and prolonged stable disease. CONCLUSIONS: Olaparib combined with irinotecan demonstrated activity in pediatric tumors, which was enriched among tumors that exhibited aneuploidy.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 A Novel Homozygous GALNT3 Deletion in Hyperphosphatemic Familial Tumoral Calcinosis Presenting with Subcutaneous Calcifications and Raynaud's Phenomenon in an Adult Patient: A Case Report. Molecular syndromology 47.5 2 Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies. Frontiers in oncology 65.42 3 CAR T-cell therapy in pediatric brain tumors: a narrative review with comparative analysis of clinical trial eligibility criteria. Frontiers in oncology 91.0 4 Liver resection is associated with better survival than TACE for hepatocellular carcinoma modestly beyond Milan criteria: a multicenter propensity-matched analysis. Frontiers in oncology 68.52 5 Case Report: a rare pediatric case series of multiple endocrine neoplasia type 2B presenting with laryngotracheal involvement. Frontiers in endocrinology 53.0 6 Kidney transplantation outcomes in children with WT1-associated kidney disease: a single-center cohort study. Frontiers in pediatrics 57.0 7 Prevalence and effects on outcomes of intracranial tumors and structural alterations in children with central precocious puberty and early and fast puberty. Frontiers in endocrinology 77.2 8 Laparoscopic liver resection for pediatric liver tumors: a systematic review and meta-analysis. Frontiers in pediatrics 73.0 9 Expanding HPV prevention across the life course: evidence on vaccine effectiveness in adults. Frontiers in public health 62.1 10 Healthcare-associated post-neurosurgical meningitis caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in an Infant: A case report. IDCases 51.9 11 Does the surgical route matter in cerebellar mutism syndrome? Comparing transvermian and telovelar approaches for pediatric posterior fossa tumors. Brain & spine 63.0 12 Oral Candida infection and colonization in pediatric patients with cancer: risk factors, species distribution, and antifungal susceptibility. Journal de mycologie medicale 52.4 13 AEG-1/MTDH: A central regulator of tumor progression, metabolic adaptation, and therapeutic resistance in gliomas. Tissue & cell 67.44 14 Determinants of mammography screening uptake among women attending family health centers in Ankara, Türkiye: a cross-sectional study. BMC health services research 59.0 15 Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers. American journal of medical genetics. Part A 65.2 16 Outcomes of Children With Orbital Rhabdomyosarcoma, 1991-2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatric blood & cancer 76.3 17 Listeria monocytogenes meningitis beyond the neonatal period: a multicenter case series of previously unpublished pediatric cases from Türkiye. European journal of pediatrics 56.9 18 Longitudinal evaluation of sleep disturbances in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Journal of cancer survivorship : research and practice 66.9 19 Age and sex differences in the global cancer burden. Cancer causes & control : CCC 39.4 20 Cancer information seeking and awareness of multi-cancer detection tests among U.S. adults: a cross-sectional study. Cancer causes & control : CCC 66.0 21 Combined glue embolization and surgical excision for management of genitourinary and perineal vascular anomalies in pediatric and adolescent patients assigned female at birth. Journal of pediatric and adolescent gynecology 59.3 22 "The less they talk about it, the more we think about it": a qualitative interview study of the existential agency of children and young people when they are relatives of a family member dying from cancer in a hospice in Denmark. BMC palliative care 57.5 23 Cellular adhesion-dependent 3D morphogenesis indicating brain tumor aggressiveness and chemosensitivity in spherical cavity culture. Experimental hematology & oncology 62.4 24 Multimodal single-cell profiling identifies nclTECs and links chromatin remodeling to TEC differentiation and self-antigen expression modes. iScience 57.4 25 Low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma in a pediatric liver transplant recipient: a case report. Urology case reports 45.5 26 Lower social participation and physical activity in patients with craniopharyngioma or CNS germ cell tumor: Their association with apathy. PCN reports : psychiatry and clinical neurosciences 61.9 27 Satisfaction with follow-up consultations among Swiss childhood cancer survivors: A prospective cohort study. Preventive medicine reports 65.5 28 Pediatric pulmonary tuberculosis masquerading as chest neoplasms. Radiology case reports 55.4 29 School re-entry for children and adolescents with cancer: A qualitative study from the perspectives of school personnel. Asia-Pacific journal of oncology nursing 58.4 30 Co-designing a prototype teaching intervention on triadic communication for healthcare professionals working with young people with cancer. PEC innovation 58.7 31 Family and sexual functioning among women diagnosed with cervical cancer in Urban Ghana: A mixed-methods study. Women's health (London, England) 62.0 32 Targeting ABCB6 induces ferroptosis in osteosarcoma cells via HIF1A/GPX4 pathway. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 68.0
PATIENT-FRIENDLY SUMMARY

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic